The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. The Revised International Prognostic Scoring System (IPSS-R) provides a recently refined method for clinically evaluating the prognosis of patients with MDS. Molecular profiling has recently generated extensive data describing critical hematopoietic molecular and biologic derangements contributing to clinical phenotypes. Current molecular insights have demonstrated roles of specific somatic gene mutations in the development and clinical outcomes of MDS, including their propensity to progress to more aggressive stages, such as acute myeloid leukemia. This article focuses on these recently reported clinical and underlying pathogenetic findings. The discussion provides a synthesis of the prognostic clinical, molecular, and biologic abnormalities intrinsic to the aberrant marrow hematopoietic and microenvironmental influences in MDS. (JNCCN 2013;11:877-885) 
The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. Factors associated with the clinical and biologic nature of MDS must incorporate the 2 major features of the disease: the defective differentiation of hematopoietic cells resulting in marrow failure with associated peripheral blood cytopenias, and expansion of the abnormal clone in patients who undergo evolution to or toward acute myeloid leukemia (AML). Pathogenetic mechanisms contributing to clinical phenotypes relate to critical molecular and biologic features.
This article focuses on recently reported advances that describe major components of these variable clinical and underlying pathogenetic features. The discussion delineates molecular and biologic features intrinsic to the aberrant marrow hematopoietic and microenvironmental influences in MDS. Particular attention is given to the prognostic features associated with disease stability or progression.
Clinical Features Prognostic Characterization
The International Prognostic Scoring System (IPSS) has been an important standard for assessing the prognosis of adult patients with untreated primary MDS. 1 However, since its publication in 1997, additional prognostic systems have been suggested providing other parameters to indicate meaningful differences in clinical outcomes, [2] [3] [4] [5] and the WHO hematopathologists added a morphologic refinement of the French-American-British classification. 6, 7 In addition, the WHO Prognostic Scoring System (WPSS) 2, 3 provided new insights into prognostic variables, adding red blood cell (RBC) transfusion dependence along with IPSS cytogenetic classification and WHO dysplastic categories. Importantly, newer cytogenetic groupings have been reported to be prognostically valuable and to refine those features used in the IPSS. 8 To refine the IPSS and evaluate many of the suggested prognostic features defined over the past decade, the International Working Group for Prognosis in MDS project assembled a large combined database of 7012 patients with untreated primary MDS from multiple institutions in 11 countries for more precise analysis. 9 This system comprehensively integrated the numerous known clinical features into a method that analyzed prognosis more precisely than the initial IPSS. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system (the Revised IPSS [IPSS-R]). 10 Novel components of this scoring method include 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of several less common cytogenetic subsets; splitting the low marrow blast percentage value; and depth of cytopenias. This model defined 5 major prognostic categories, rather than the 4 present in the IPSS. A major component of this IPSS-R schema was the provision of 5 cytogenetic subgroups (vs 3 in the IPSS) based on an increased number of specific prognostic chromosomal categories (15) as developed by the new cytogenetic system (8) versus 7 in the IPSS. This increase in defined cytogenetic categories occurred because a larger number of patients were available for analysis of some of the relatively rare cytogenetic categories, thus improving the prognostic accuracy.
Splitting patients with fewer than 5% marrow blasts into those with 0% to 2% and greater than 2% to fewer than 5% provided groups with verylow-risk versus low-risk features. The presence of 10% to 20% marrow blasts had a similar effect on clinical outcomes, as did 21% to 30% blasts; thus, these 2 categories were combined in the predictive model. Scoring the depth of cytopenias according to the IPSS-R through subdivision at clinically and statistically relevant cut points rather than solely counting their presence was useful. The degree of anemia is an important correlate of poor clinical outcomes in MDS and seems to be a good surrogate for RBC transfusion dependence. 11 In this regard, low hemoglobin levels have recently replaced RBC transfusion dependence as a prognostic parameter of the WPSS. 11 Underlying this finding, chronic anemia may contribute to the high nonleukemic mortality related to cardiac disease in patients with MDS. 2, 3, 11 The other cytopenic IPSS-R cut points (ie, low neutrophil and platelet levels) also have clinical relevance. [12] [13] [14] [15] [16] Various other differentiating features in the IPSS-R were additive to the 5 major parameters for predicting survival, albeit not for AML evolution: age, performance status, serum ferritin, and lactate dehydrogenase levels. The impact of age was a major prognostic parameter for overall survival, which was previously shown with the IPSS and in other studies. 1, 2, [17] [18] [19] [20] Although these features had some additive impact on survival, this effect was relatively minor compared with that of the 5 major features used to define the IPSS-R.
Thus, compared with the IPSS, the IPSS-R showed improved predictive prognostic power with more precise prognostic categories (5 vs 4 groups in the IPSS). In particular, a substantial proportion of the patients previously placed within the IPSS intermediate-1 and -2 categories (≈20%) were more precisely separated into all 5 IPSS-R categories. For therapeutic decision-making, the IPSS-R very low and low categories correspond with the lower risk categories, and high and very high categories with the higher risk categories. Recent investigations from several centers have validated the clinical utility of this IPSS-R system for risk analysis of patients with MDS in a variety of settings. [21] [22] [23] [24] Flow cytometric studies showing diagnostic and prognostic value for analysis of MDS bone marrow have recently been reported, showing the potential clinical impact of this technology. 25 This approach is addressed by van de Loosdrecht and Westers elsewhere in this issue.
Biologic and Molecular Abnormalities
Multifactorial pathogenetic features underlying MDS relate to primary disease-specific intrinsic hematopoietic stem cell (HSC) and progenitor lesions combined with an altered marrow microenvironmental milieux. These findings show that cytogenetic abnormalities, oncogenic mutations, and epigenetic changes, are associated with disease progression in MDS. A major final common pathogenetic pathway causing ineffective hematopoiesis in MDS has been the varying degrees of apoptosis of the hematopoietic precursors and their progeny, with increased apoptosis in lower-risk compared with higher-risk disease. [26] [27] [28] [29] [30] [31] This apoptotic process in hematopoietic precursors is increased early in the disease with associated peripheral cytopenias and diminishes with disease progression, thus permitting expansion of the abnormal clone.
Marrow Stromal Influences
Abnormal marrow stromal influences, including altered function of intramedullary phagocytic cells and an excess of inflammatory cytokines, strongly affect these altered hematopoietic processes. HSCs and myeloid progenitors in MDS have recently been characterized. A report of recent data using purified immunophenotypically defined human HSCs from MDS samples transplanted into immunodeficient mice suggested that HSCs are disease-initiating cells in MDS. 30 Fluorescence in situ hybridization and gene expression data from purified HSCs of patients with del(5q) MDS also suggested an HSC origin for MDS. [31] [32] [33] [34] Loss of the more mature granulocytemacrophage progenitors (GMPs) in the bone marrow of lower-risk patients with MDS (ie, with <5% marrow blasts) was demonstrated. 30 Associated with this, in lower-risk compared with higher-risk MDS, increased prophagocytic calreticulin molecules were present on the GMP compared with antiphagocytic molecules (CD47). 30 Thus, this reduction in GMPs in lower-risk MDS seems to be secondary to both increased programmed cell removal by intramedullary macrophages and to programmed cell death (apoptosis), the former being caused by upregulation of calreticulin. In higher-risk MDS, the frequency of myeloid progenitors in the bone marrow was higher than in lower-risk MDS, related to their evasion of phagocytosis through upregulation of CD47 30 and decreased apoptosis.
27,30 These findings of the expanded number of abnormal progenitors in higher-risk disease are consistent with these altered mechanisms of cell removal or cell death in MDS being associated with disease progression to or toward AML.
Molecular Features
Recent findings have provided major molecular insights into specific gene mutations playing critical roles in the development and clinical outcome of MDS, and its propensity to progress to a more aggressive stage. Somatic point mutations have been identified in more than 70% of patients with MDS, including most cases with a normal karyotype. These mutations are major predictors of clinical phenotype, and may also predict prognosis independent of existing clinical variables. 35, 36 Prognostic Molecular Abnormalities Molecular investigations have indicated that both single-gene mutations and global differential expression profiles of genes from marrow cells have major prognostic value. 37, 38 These abnormalities involve genes engaged in molecular signaling and differentiation, regulation of cell cycle progression, apoptosis, transcription, translation, and epigenetics (Table 1) .
Genetic alterations have included oncogenic mutations, amplifications or deletions, transcriptional RNA splicing abnormalities, epigenetic changes, and/or altered telomere dynamics.
Investigations using next-generation DNA sequencing technology showed a substantial number of somatic gene mutations in marrow from patients with MDS. 39 These mutations were found in 51% of the patients in at least 1 of 18 genes, including those with normal cytogenetics. Most of these mutations caused loss of function rather than being activating mutations. Some were mutually exclusive, whereas others (eg, TET2 mutations, the most commonly found mutation in ≈20% of patients) were associated with other mutations, suggesting the codependence of these mutations being related to disease status. Five gene mutations (TP53, EZH2, ETV6, RUNX1, ASXL1), present in 3% to 14% of the patients, were associated with poor overall survival ( Table 1) . Although these data did not relate to the potential for patients to develop AML, some of these mutations were associated with distinct clinical phenotypes and prognosis regarding survival. TP53 mutations were mainly seen in higher-risk patients, whereas mutations in EZH2 and ASXL1 were generally present in those with lower risk. RUNX and N-RAS mutations were often associated with chromosome 7 abnormalities. Having at least one of these abnormalities was additive to IPSS risk regarding patient survival, with their presence shifting patients to the next higher IPSS category. In other studies, TET2 gene mutations were also found in approximately 20% of patients with MDS, which were associated with improved prognosis. 40, 41 In a recent study of 738 patients with MDS in which 111 candidate genes were evaluated, 41 highconfidence oncogenic mutations were found. 42 One or more molecular lesions was present in 78% of the patients, 15% with pairwise associations. More than 10% of the patients had 4 gene mutations (SF3B1, TET2, SRSF2, ASXL1); 43% had 2 or 3 mutations. U2-spliceosome mutations were found in 51% of the patients. These abnormalities were generally mutually exclusive, but did co-occur with DNA methylation genes. These findings provided prognostic information in which an inverse correlation was seen between gene mutation number and overall and leukemia-free survival. Two new inactivating mutations were found (CUX1, IRF1). Mutations in CUX1 had a negative prognostic impact (Table 1) .
Studies have recently defined numerous molecular abnormalities in chronic myelomonocytic leukemia (CMML). 43 Nine mutations were particularly frequent, of which 93% patients had at least one such lesion (TET2, 61%; SRSF2, 47%; ASLX1, 44%; RAS, 30%; RUNX, 22%; CBL, 19%; EZH2, 11%; JAK2, 7%; IDH1/2, 5%; Table 1 ). The SRSF2 mutation, a member of the spliceosome complex, was generally associated with a good prognosis, 43 whereas worse prognosis was found in patients with U2AF1 and DNMT3A mutations 44 (Table 1) . SETBP1 mutations were recently found in a variety of myeloid malignancies (in 15% of patients with CMML and secondary AML, 7% of those with chronic myelogenous leukemia in blast crisis). 45 Increased SETBP1 expression was found in MDS and therapy-related AML. This gain-of-function mutation regulates gene expression, increasing HoxA9/10 and decreasing RUNX1 expression. This mutation Gene mutation associated with chronic myelomonocytic leukemia.
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was shown to be acquired during leukemic evolution, have increased expression in AML, and be associated with a poor prognosis 46 (Table 1) . Of interest, SETBP1 is also associated with congenital cancer susceptibility (Schinzel-Giedion syndrome). 45 Patients with del(5q) cytogenetics have a distinctive form of MDS, with a remarkably high erythroid and cytogenetic responsiveness to the drug lenalidomide. However, the durability of that response and the potential for AML evolution in these patients are variable. Long-term outcomes are poorer in patients with del(5q) MDS with additional cytogenetic lesions than in those with del(5q) alone. 47 In contrast to earlier investigations, recent data using very sensitive next-generation sequencing techniques showed that a higherthan-expected subset of lower-risk patients with del(5q) MDS (18%) had TP53 mutations. 48 The patients with mutated TP53 had poorer erythroid and cytogenetic responses to lenalidomide and a higher potential for AML evolution. These findings, with prognostic and therapeutic implications for TP53 mutations (Table 1) , indicate the importance of molecular findings to help define existing heterogeneity within even an MDS subtype with a single cytogenetic abnormality.
Abnormal Transcriptional mRNA Splicing
Recurrent somatic mutations in components of the spliceosome have recently been identified with wholegenome and whole-exome sequencing of samples from patients with MDS. [49] [50] [51] [52] As a class, these mutations, including U2AF35, ZRSR2, SRSF2, and SF3B1, are remarkably common, affecting 45% to 85% of patients with MDS, depending on the morphologic subtype. 49 Most of the mutations, which occurred in a mutually exclusive manner, affected genes involved in pre-mRNA processing, inducing abnormal RNA splicing and compromised hematopoiesis. Splicing mutations are generally enriched in diseases characterized by morphologic dysplasia, such as MDS, CMML, and AML with myelodysplasia-related changes. These data indicate that genetic alterations of the major transcriptional splicing components could be translated into dysfunctional proteins contributing to MDS pathogenesis. Further investigations using massively parallel sequencing technology have extended the implications of mRNA splicing abnormalities in MDS, showing mutations in SF3B1 in 20% of 354 patients, and have a high degree of specificity (65%) in patients with ring sideroblasts. 50 In addition, patients with this mutation had improved survival compared with those lacking the mutation (Table 1) .
Single Nucleotide Polymorphisms
In addition to standard metaphase cytogenetic analysis, single nucleotide polymorphism analysis (SNP-A) has usefully expanded the ability to analyze chromosomal abnormalities and improve the prognostic assessment of patients with MDS, including permitting evaluation of those with or without cytogenetic abnormalities. 53 Approximately 75% of patients with MDS had cryptic cytogenetic lesions shown by SNP-A compared with only approximately 50% by standard metaphase cytogenetics. This was particularly evident in those with normal cytogenetics, wherein 58% of the patients had abnormal SNP-A results. Patients with SNP abnormalities had poorer clinical outcomes than those lacking these findings. Recently, analysis of patients with hypoplastic MDS also showed a substantial increase in clonal abnormalities by SNP-A compared with standard metaphase cytogenetics. 54 The SNP abnormalities were higher in patients with hypoplastic MDS than in those with aplastic anemia, including those with normal metaphase cytogenetics. Of interest, a portion of the patients with aplastic anemia had evolving abnormalities, suggesting that they may have initially had MDS.
MicroRNA and Ribosomal Biogenesis Abnormalities
Additional molecular features in del(5q), such as ribosomal biogenesis dysfunction and altered microRNA (miRNA) levels, also contribute to the phenotype of these patients. They have haploinsufficiency of the ribosomal protein RPS14, which activates p53, causing marrow cell apoptosis, but is blocked by the drug lenalidomide. 55, 56 The patients with del(5q) and low RPS14 expression had better survival than those lacking this abnormality. 57 Additionally, the thrombocytosis seen in these patients relates to the decreased level of several microRNAs (miR145, miR146). 58 Selective overexpression of miR181 family members was particularly detected in higher-risk MDS. 59 In addition, patients with lower-risk MDS with such overexpression had poorer survival.
Gene Expression Deregulation
Deregulated gene pathways and RNA expression have been shown in MDS. Using microarray techniques, distinctive gene expression profiles (GEPs) with poorrisk gene expression signatures of MDS marrow CD34 + cells were shown in patients whose disease transformed to AML within a relatively short time (ie, 14 months) compared with those with stable disease. 37 Other GEP studies have shown prognostic import for MDS. 38 Among the most significantly deregulated gene pathways in early MDS were immunodeficiency, apoptosis, and chemokine signaling, whereas advanced MDS was characterized by deregulation of DNA damage response and checkpoint pathways.
60

Epigenetic Alterations
Epigenetic mechanisms, such as DNA methylation and histone modifications, drive clonally propagated changes in gene expression, and these acquired abnormalities can therefore serve as molecular mediators of pathway dysfunction in neoplasia. 61 MDS is characterized by frequent epigenetic abnormalities, including the hypermethylation of genes that control proliferation, adhesion, and other characteristic features of this leukemia. Alterations in DNA methylation have been implicated in the pathogenesis of MDS, although the underlying mechanism remains largely unknown. DNA hypermethylation of a variety of genes may be found in patients with early-stage MDS, affecting disparate cell functions, including CDKN2A (cell cycle), DAPK1, RIL (adhesion, motility), CDH1, and CDH13 (adhesion, motility). Disease progression is associated with additional epigenetic events. MDS and secondary AML display unique patterns and an abundance of aberrant DNA methylation. 62 Modification of this hypermethylation gene profile is being used therapeutically in treating patients with MDS with hypomethylating agents such as 5-azacytidine and decitabine, often with beneficial results.
Methylation of CpG dinucleotides is mediated by DNA methyltransferases (DNMTs), including DNMT1, DNMT3A, and DNMT3B. DNMT3A mutations have been reported in patients with de novo AML, and more recently heterozygous mutations of DNMT3A were identified in 8% of patients with MDS. 63 These patients had poorer overall survival and more rapid progression to AML than those without these mutations (Table 1) . These findings suggest a link to the treatment responses to hypomethylating agents (DNMT inhibitors) seen in MDS.
Altered Telomere Dynamics
Telomerase, containing the human telomerase reverse transcriptase (hTERT) catalytic subunit and a small integral RNA component, synthesizes telomeres, the ends of eukaryotic chromosomes. Inhibition of telomerase activity causes cellular senescence and cell death. Telomere dynamics are altered in MDS, with telomere shortening along with disease progression, leading to genetic instability with susceptibility to further molecular alterations as the disease persists. 64, 65 Telomerase activity and hTERT expression is increased in marrow cells from patients with MDS, and patients with more severe disease showed significantly higher levels of hTERT expression and telomerase activity than those with more favorable disease. 66 These data suggest the potential role of altered telomere dynamics in MDS progression.
Summary
The IPSS-R, with its risk-based method of characterizing primary untreated MDS, was shown to possess improved prognostic utility for assessing survival and AML evolution compared with the IPSS and other prior classification systems. As such, the IPSS-R is beneficial for clinical determination of prognostic status and for aiding the design and analysis of clinical trials for this disease. Combining these clinical features with the recently defined molecular lesions should markedly enhance the ability to provide more precise diagnostic and prognostic analyses for these patients.
The biologic and molecular data presented herein provide insights into mechanisms underlying MDS and their propensity to progress to more aggressive stages. The novel findings of programmed cell removal and cell death (apoptosis) contribute to the understanding of stage-dependent ineffective hematopoiesis in MDS. The specific genetic alterations present in individual patients with MDS explain much of the clinical heterogeneity exemplified by this spectrum of diseases. Given the low incidence and variety of single-gene mutations in MDS, individual genetic lesions are unlikely to be the sole disease-causing abnormalities in these disorders. Rather, a combination of cooperative mutations may be required, possibly together with epigenetic changes of specific gene expression. Defining lesions of the RNA splicing machinery associated with transcriptional regulatory abnormalities in MDS has opened key avenues for exploring underlying pathogenetic features. Therefore, these findings have the potential to engender discovery of targets for biospecific therapy. Extending the use of more comprehensive and sensitive methods for molecular profiling using next-generation sequencing techniques to evaluate MDS marrow cells will likely define further critical biologic lesions underlying this spectrum of diseases. 
